Trial record 14 of 175 for:    "gastrointestinal stromal tumor"

Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors

This study has been completed.
Sponsor:
Collaborator:
Takeda Bio Development Center, Ltd
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT00254267
First received: November 14, 2005
Last updated: February 26, 2014
Last verified: February 2014
  Purpose

The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.


Condition Intervention Phase
Advanced Gastrointestinal Stromal Tumor
Drug: AMG 706
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • The objective response rate as assessed by modified RECIST [ Time Frame: Every 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Duration of response, progression-free survival, time to response, overall survival, PK and safety profile [ Time Frame: imaging, every 8 weeks; survival, every 6 months; PK, Days 1,15, 29, 43, 57, every 2 weeks in week 9 to 16, and every 4 weeks thereafter; ] [ Designated as safety issue: Yes ]

Enrollment: 35
Study Start Date: November 2005
Study Completion Date: December 2012
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm One
AMG 706 125mg, oral, once a day
Drug: AMG 706
AMG 706 125mg, oral, once a day

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of histological confirmed GIST
  • Had prior imatinib mesylate therapy
  • Has at least 1 measurable leasion by modified RECIST

Exclusion Criteria:

  • Central nervous system tumor involvement requiring treatment
  • History of myocardial infraction
  • Uncontrolled hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00254267

Sponsors and Collaborators
Amgen
Takeda Bio Development Center, Ltd
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided by Amgen

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT00254267     History of Changes
Other Study ID Numbers: 20050129
Study First Received: November 14, 2005
Last Updated: February 26, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Amgen:
Gastrointestinal Stromal Tumor, Imatinib Mesylate Resistance, Phase2 study, AMG 706

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Imatinib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 29, 2014